The day in pharma, read in minutes.
Zealand Pharma Opens Cambridge Hub, Expands Biologics and Hybrid Modalities
Zealand Pharma opens its 53,600 RSF Cambridge hub, expanding from peptides into biologics and hybrid modalities under its Metabolic Frontier 2030 strategy.
EMA Advances New Pharmaceutical Legislation Implementation, Prioritising Antibiotic Vouchers and Regulatory Sandbox
EMA Sets 20 November 2026 Deadline for Type IA Variations to Secure Year-End Outcomes
Regeneron Achieves 73% Response Rate with Ubamatamab in Phase 1/2 LGSOC Trial
Achieve Life Sciences Appoints Benjamin Halladay as CFO Ahead of Cytisinicline Commercialization
Latest news
11 storiesSpyGlass Pharma Acquires AVS in $13M Deal to Secure IOL Manufacturing
SpyGlass Pharma acquires IOL manufacturer AVS for $13M, securing Phase 3 supply and expanding its drug-delivery lens portfolio.
60 Degrees Pharmaceuticals Releases Tafenoquine Babesiosis Interim Data
60 Degrees Pharmaceuticals releases tafenoquine babesiosis interim data October 6, with no FDA-approved therapy currently existing for the indication.
Regeneron Achieves Phase 2 COURAGE Trial Milestone Confirming Trevogrumab Preserves Muscle Mass During GLP-1 Weight Loss
Regeneron's COURAGE trial shows trevogrumab preserved up to 70% of muscle lost during semaglutide treatment, advancing plans for a Phase 2 combination trial.
AbbVie Achieves 76-Week Repigmentation Data for Upadacitinib in Non-Segmental Vitiligo
AbbVie's 76-week Viti-Up data show rising repigmentation rates for upadacitinib in NSV, extending the regulatory and manufacturing dossier for the EU-approved JAK inhibitor.
Cardinal Health Signs CVS Health Distribution Extension
Cardinal Health extends its pharmaceutical distribution agreement with CVS Health through June 2032 via a binding LOI, preserving existing supply chain scope.
Integrated Process Solutions for Modern Manufacturing
Frederic Dietrich, Managing Director of Dec Group, discusses the evolution from powder handling to integrated process solutions, automation, and AI in pharma manufacturing.
20261001144238.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
Lilly Retatrutide Phase 3 Trial Yields 20.8% Diabetes Weight Loss
Lilly's retatrutide delivers 20.8% weight loss in Phase 3, signalling a third high-volume incretin asset approaching the manufacturing pipeline.
Roche Fenebrutinib Gets FDA Priority Review In Two MS Indications
FDA grants Roche Priority Review for fenebrutinib in RMS and PPMS, compressing CMC and manufacturing readiness timelines to six months.
Acrotech Launches Topical PDE4 Inhibitor ADQUEY In US Via FDA Nod
Acrotech Biopharma launches ADQUEY, an FDA-approved non-steroidal PDE4 inhibitor topical, for adults and pediatric patients aged 2 and older in the US.
Shilpa Biologicals Launches SB HiMax Biologics Speed Platform
Shilpa Biologicals launches SB HiMax, an integrated biologics development platform targeting compressed CDMO timelines for biotech sponsors.
Lilly Zepbound Beats Wegovy HD Weight Loss In 72-Week Trial
Lilly's 72-week data shows tirzepatide 15 mg outperforming semaglutide 7.2 mg by 4.5% in weight loss, intensifying GLP-1 capacity planning decisions.
Worth your time this week
Sanofi And Regeneron Expand Immunology Alliance In $8B Grand Deal
Roche Phase III PFS Gains Hits Ahead Of Dual 2026 PDUFA Deadlines
Regeneron & Sanofi Sign $8B Expansion For Four Long Antibodies
